Agenus Inc 的 Form 4/A 修正申報
修正MiNK Therapeutics, Inc.（INKT），2023/5/26 申報
- 申報編號
- 0000950170-23-024567
- 申報時間
- 2023/5/26
- 10b5-1 計畫
- 沒有勾選
- 原始申報日
- 2023/5/5
這份申報沒有列出任何交易。沿用原件裡沒有重述的 4 筆交易。公開市場買進合計 $26.0 萬。
這份修正申報重述了 0000950170-23-018401（2023/5/5 申報）的一部分，沒有重述的交易仍然有效，列在下面。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Agenus IncCIK 0001098972 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
這份申報沒有這一類的交易。
沿用原件的交易
這份修正申報只重述了原件的一部分。原件其他的交易仍然有效，網站的交易表把它們算在這份修正申報底下。
來自 0000950170-23-018401（2023/5/5 申報）。
非衍生性證券（表 I）
原件的附註
這幾筆交易的價格在原件上引用的附註。
- F1
Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $0.9144 to $1.20).
表 I 有 1 筆交易的價格引用這則附註。
- F2
Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.
表 I 有 2 筆交易的價格引用這則附註。
- F3
Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $1.20 to $1.25).
表 I 有 1 筆交易的價格引用這則附註。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
On May 5, 2023, Agenus Inc. ("Agenus") disclosed a transaction involving 100,000 Mink Therapeutics shares. It agreed to purchase such shares from Garo Armen, the CEO and Chairman of Agenus, at Dr. Armen's original purchase price, which was lower than the market price at the time of the proposed purchase. This action was taken to prevent any perception of Dr. Armen benefitting from low-cost purchases while Agenus was buying at higher prices in separate transactions. However, due to the shares being in Dr. Armen's IRA account, their transfer was prohibited, leading the broker to reverse the sale and decline Agenus' payment. Consequently, the Mink Therapeutics shares were returned to Dr. Armen, and the purchase price was given back to Agenus. This amendment accounts for the changes in Agenus' ownership following the reversal of this transaction.